The authors wish to thank the personnel of the IRCM animal facility team, the histology (RHEM) platform, the Affymetrix platform of Montpellier and Dr Caroline Mollevi from the Biostatistics platform at ICM for their help in this project. The constant support of ICM and SIRIC Montpellier-Cancer is gratefully acknowledged.International audiencePatient derived xenografts (PDXs) are increasingly appreciated models in cancer research, particularly for preclinical testing, as they reflect the patient's tumor biology more accurately than cancer cell lines. We have established a collection of 20 breast PDXs and characterized their biological and clinical features, as well as their genetic stability. While most PDXs originated from triple negative ...
Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to...
BACKGROUND: Metastatic breast cancer (mBC) is a complex and life-threatening disease and although it...
Development of candidate cancer treatments is a resource-intensive process, with the research commun...
The authors wish to thank the personnel of the IRCM animal facility team, the histology (RHEM) platf...
We established patient-derived xenografts (PDX) from human primary breast cancers and studied whethe...
Patient-derived xenografts (PDXs) have become a prominent cancer model system, as they are presumed ...
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long...
Despite advances in the treatment of patients with early and metastatic breast cancer, mortality rem...
In this issue of Cell Reports, Li et al. show that the analysis of genetic changes in patient-derive...
International audienceABSTRACT: INTRODUCTION: Identification of new therapeutic agents for breast ca...
Human breast cancer is characterized by a high degree of inter-patients heterogeneity in terms of hi...
SummaryThe inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in ...
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical stud...
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-cli...
Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to...
BACKGROUND: Metastatic breast cancer (mBC) is a complex and life-threatening disease and although it...
Development of candidate cancer treatments is a resource-intensive process, with the research commun...
The authors wish to thank the personnel of the IRCM animal facility team, the histology (RHEM) platf...
We established patient-derived xenografts (PDX) from human primary breast cancers and studied whethe...
Patient-derived xenografts (PDXs) have become a prominent cancer model system, as they are presumed ...
Patient-derived xenograft (PDX) models of a growing spectrum of cancers are rapidly supplanting long...
Despite advances in the treatment of patients with early and metastatic breast cancer, mortality rem...
In this issue of Cell Reports, Li et al. show that the analysis of genetic changes in patient-derive...
International audienceABSTRACT: INTRODUCTION: Identification of new therapeutic agents for breast ca...
Human breast cancer is characterized by a high degree of inter-patients heterogeneity in terms of hi...
SummaryThe inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in ...
Patient-derived xenografts (PDXs) are resected human tumors engrafted into mice for preclinical stud...
The inter- and intra-tumor heterogeneity of breast cancer needs to be adequately captured in pre-cli...
Estrogen receptor α-positive (ER-positive) or 'luminal' breast cancers were notoriously difficult to...
BACKGROUND: Metastatic breast cancer (mBC) is a complex and life-threatening disease and although it...
Development of candidate cancer treatments is a resource-intensive process, with the research commun...